US Patent

US8729085 — Pharmaceutical composition

Formulation · Assigned to Sumitomo Dainippon Pharma Co Ltd · Expires 2026-05-26 · 0y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition for oral administration that includes lurasidone hydrochloride as an active ingredient and exhibits consistent elution behavior regardless of the active ingredient's content.

USPTO Abstract

A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.

Drugs covered by this patent

Patent Metadata

Patent number
US8729085
Jurisdiction
US
Classification
Formulation
Expires
2026-05-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Sumitomo Dainippon Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.